menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

PPIs and Antiplatelet Therapy: Weighing the Benefits and Risks

close
PPIs and Antiplatelet Therapy: Weighing the Benefits and Risks
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    One of the biggest risks of antiplatelet therapy is gastrointestinal bleeding. Because of this risk, patients on the antiplatelet clopidogrel are often prescribed proten pump inhibitors, or PPIs. However, there are also concerns about PPIs decreasing the efficacy of clopidogrel. What approach should physicians take for patients at moderate to high risk for upper GI bleeding? Host Dr. Janet Wright welcomes Dr. Deepak Bhatt, chief of cardiology at the VA Boston Healthcare System, director of the Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital & VA Boston Healthcare System, and associate professor of medicine at Harvard Medical School, to discuss evidence about the potential interactions between PPIs and clopidogrel based on findings from the COGENT trial. 

    Produced in Cooperation with

    American College of Cardiology

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    One of the biggest risks of antiplatelet therapy is gastrointestinal bleeding. Because of this risk, patients on the antiplatelet clopidogrel are often prescribed proten pump inhibitors, or PPIs. However, there are also concerns about PPIs decreasing the efficacy of clopidogrel. What approach should physicians take for patients at moderate to high risk for upper GI bleeding? Host Dr. Janet Wright welcomes Dr. Deepak Bhatt, chief of cardiology at the VA Boston Healthcare System, director of the Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital & VA Boston Healthcare System, and associate professor of medicine at Harvard Medical School, to discuss evidence about the potential interactions between PPIs and clopidogrel based on findings from the COGENT trial. 

    Produced in Cooperation with

    American College of Cardiology

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/8/21